Activation of PKC-ε counteracts maturation and apoptosis of HL-60 myeloid leukemic cells in response to TNF family members

Protein kinase C (PKC)-ε, a component of the serine/threo-nine PKC family, has been shown to influence the survival and differentiation pathways of normal hematopoietic cells. Here, we have modulated the activity of PKC-ε with specific small molecule activator or inhibitor peptides. PKC-ε inhibitor and activator peptides showed modest effects on HL-60 maturation when added alone, but PKC-ε activator peptide significantly counteracted the pro-maturative activity of tumor necrosis factor (TNF)-α towards the monocytic/macrophagic lineage, as evaluated in terms of CD14 surface expression and morphological analyses. Moreover, while PKC-ε inhibitor peptide showed a reproducible increase of TNF-related apoptosis inducing ligand (TRAIL)-induced apoptosis, PKC-ε activator peptide potently counteracted the pro-apoptotic activity of TRAIL. Taken together, the anti-maturative and anti-apoptotic activities of PKC-ε envision a potentially important proleukemic role of this PKC family member

Vaginal Lactoferrin Modulates PGE 2

Inflammation plays an important role in pregnancy, and cytokine and matrix metalloproteases (MMPs) imbalance has been associated with premature rupture of membranes and increased risk of preterm delivery. Previous studies have demonstrated that lactoferrin (LF), an iron-binding protein with anti-inflammatory properties, is able to decrease amniotic fluid (AF) levels of IL-6. Therefore, we aimed to evaluate the effect of vaginal LF administration on amniotic fluid PGE2 level and MMP-TIMP system in women undergoing genetic amniocentesis. One hundred and eleven women were randomly divided into controls (n = 57) or treated with LF 4 hours before amniocentesis (n = 54). Amniotic fluid PGE2, active MMP-9 and MMP-2, and TIMP-1 and TIMP-2 concentrations were determined by commercially available assays and the values were normalized by AF creatinine concentration. PGE2, active MMP-9, and its inhibitor TIMP-1 were lower in LF-treated group than in controls (p < 0.01, p < 0.005, and p < 0.001, resp.). Conversely, active MMP-2 (p < 0.0001) and MMP-2/TIMP-2 molar ratio (p < 0.001) were increased, whilst TIMP-2 was unchanged. Our data suggest that LF administration is able to modulate the inflammatory response following amniocentesis, which may counteract cytokine and prostanoid imbalance that leads to abortion. This trial is registered with Clinical Trial number NCT02695563

Fluxiod jumps coupled high critical current density of nano-Co3O4 doped MgB2

Polycrystalline MgB2 samples with 0, 2, 4 and 6 percent added nano-Co3O4 being synthesized by vacuum (10-5 Torr) annealing at 750 0C for three hours each are found to be nearly single phase with presence of only a small quantity of Mg/MgO in pristine sample and in addition the Co2O3 in doped compounds. All the samples exhibited clear and sharp diamagnetic transitions at around 38 K, in Zero-field-cooled (ZFC) magnetic susceptibility measurements with sizeable signal. The Field cooled (FC) measurements though having sharp transitions, but showed a very small signal, indicating high level of pinning centers in these samples. Further some of the doped samples exhibited Paramagnetic-Meissner-Effect (PME) in applied field of 5 Oe. The critical current density (Jc), being estimated by invoking Bean model for the pristine compound increase by nearly an order of magnitude for 2 and 4 percent nano-Co3O4 doping and later the same decreases sharply for 6 percent sample at nearly all studied temperatures and applied fields. Further the increased Jc (~ 10^8 A/cm2) is coupled with fluxiod jumps (T = 20 K and H = 1 T). Fluxiod Jumps are not seen in relatively low Jc pristine or 6 percent sample. This means the fluxiod-jumps are intrinsic only to the high Jc samples.Comment: 14 pages including TEXT + Figs. Comments Welcome ([email protected]) OR [email protected]

Mucus trap in coral reefs: formation and temporal evolution of particle aggregates caused by coral mucus

Corals exude large volumes of nutrient-containing mucus when exposed to air during low spring tides, as a protective mechanism against desiccation and UV radiation. Currents and waves of the incoming flood detach the mucus from the corals, thereby increasing organic carbon and nutrient concentrations in the reef water. During transport into the reef lagoon, a large fraction of the mucus dissolves. Roller-table experiments demonstrated that this dissolved mucus leads to the formation of marine snow. The non-dissolving gel-like fraction of the mucus rapidly accumulates suspended particles from the flood water and forms in temporal sequence mucus strings, flocs, surface films, surface layers and thick mucus floats. In a platform reef in the Great Barrier Reef, Australia, we characterized each of these mucus phases and observed the exponential increase of algal and bacterial cells in the ageing mucus aggregates. Within 3 hours, the dry weight of the aggregates increased 35-fold, chlorophyll a 192-fold, bacteria cell density 546-fold, C 26-fold, and N 79-fold. After waves destroy the buoyant mucus floats, the mucus aggregates release enclosed gas bubbles and quickly sink to the lagoon sediments, where they are consumed by the benthic community. This releases aggregate-bound nutrients, which fuel benthic and planktonic production in the lagoon. During ebb tide, corals filter the lagoon water and close the recycling loop. We conclude that coral mucus enhances the filtration capacity of coral reefs and fuels reef benthos, thereby increasing the import of oceanic particles and enhancing recycling in the reef ecosystem

Recombinant TRAIL induces miorelaxating activity in rat aortas, which is abrogated by the induction of diabetes mellitus

TNF-related apoptosis inducing ligand (TRAIL) is a member of the tumor necrosis factor (TNF) family of cytokines, which exist either as type II membrane or as a soluble protein. Although the best-characterized activity of TRAIL is represented by its anti-cancer activity, it has been recently shown that TRAIL serum levels are decreased in patients affected by atherosclerotic cardiovascular disease raising the possibility that circulating soluble TRAIL might also affect vascular biology. In this respect, it has been previously shown that TRAIL induces the in vitro release of nitric oxide by vascular endothelial cells. In order to explore the in vivo relevance of these in vitro findings, we have assessed the vascular reactivity in response to recombinant TRAIL in a more intact paradigm. For this purpose, rings (4mm long) from rat thoracic aorta were obtained by both control (3-month-old male non-diabetic Wistar rats receiving vehicle infusion) and rats in which diabetes mellitus was induced by injecting 40 mg/kg streptozotocin (SZT). After sacrifice of the animals, aortas were harvested, cleaned of connective tissue and vascular reactivity was analyzed in ex vivo immediately after harvest. During submaximal contraction with phenylephrine, incubation of aortic segments in the presence of increasing (up to 1000 ng/ml) concentrations of recombinant human TRAIL, resulted in significant (p<0.01) vaso-relaxation. The effect was dose-dependent and was completely abolished by pre incubation of the rat aortic rings with L-NAME, clearly indicating that the NOS pathway played a key role in mediating the myo-relaxating activity of TRAIL. In parallel, we have investigated whether the induction of diabetes mellitus might affect the relaxating activity of aortic rings in response to TRAIL. Diabetes mellitus was induced by destruction of pancreatic islet cells by treating rats with SZT (40 mg/kg). Non-fasting blood glucose concentrations of both SZT-diabetic rats (SZT, n = 10) and age-matched control non-diabetic rats treated with vehicle (n = 10) were measured at days 5 and 15, when animals were sacrificed with CO2. The loss of insulin secretion triggered stable hyperglycemia, as evaluated by blood glucose measurement: 260±46 and 295±55 in diabetic rats at days 5 and 15 after diabetic induction, respectively, versus 89±8 in control rats. Relaxation to TRAIL was completely abrogated in aortic rings obtained from SZT-induced diabetic rats. To the best of our knowledge, this is the first demonstration that soluble recombinant TRAIL promotes a dose-dependent myo-relaxation activity when added ex vivo to rat aortic rings, thus suggesting that it might play a physiological role in the control of vascular tone regulation. Importantly, such myorelaxating activity was completely abrogated in diabetic rats, as early as 15 days after diabetes mellitus induction by STZ injection. It should be emphasized that diabetic vascular dysfunction is a major clinical problem that predisposes patients to a variety of cardiovascular diseases. In fact, diabetic patients frequently suffer from macroscopic and microscopic vasculopathy and accelerated atherosclerosis. The loss of myo-relaxating activity is a key feature of endothelial dysfunction, which invariably precedes permanent vascular alterations. Taken together with previous data showing that TRAIL significantly counteracts the pro-adhesive activity of inflammatory cytokines on endothelial cells in vitro and displays anti-atherosclerotic activity when injected in vivo in ApoE−/−null mice, our present findings suggest that a therapeutic strategy aimed to restore the miorelaxating response to TRAIL may be suitable for improving the vascular function in diabetes mellitus

Activation of PKC-epsilon counteracts maturation and apoptosis of HL-60 myeloid leukemic cells in response to TNF family members.

Protein kinase C (PKC)-epsilon, a component of the serine/threonine PKC family, has been shown to influence the survival and differentiation pathways of normal hematopoietic cells. Here, we have modulated the activity of PKC-epsilon with specific small molecule activator or inhibitor peptides. PKC-epsilon inhibitor and activator peptides showed modest effects on HL-60 maturation when added alone, but PKC-epsilon activator peptide significantly counteracted the pro-maturative activity of tumor necrosis factor (TNF)-alpha towards the monocytic/macrophagic lineage, as evaluated in terms of CD14 surface expression and morphological analyses. Moreover, while PKC-epsilon inhibitor peptide showed a reproducible increase of TNF-related apoptosis inducing ligand (TRAIL)-induced apoptosis, PKC-epsilon activator peptide potently counteracted the pro-apoptotic activity of TRAIL. Taken together, the anti-maturative and anti-apoptotic activities of PKC-epsilon envision a potentially important proleukemic role of this PKC family member